Gen-Probe Inc, San Diego, unveiled Progensa PCA3, a new urine test that offers additional information to aid in the diagnosis of prostate cancer (PCa), which is the second most commonly diagnosed malignancy and a leading cause of cancer death in men across the globe. Current practices for detecting PCa utilize PSA and DRE as indications for biopsy.

PCA3 is a prostate-specific gene that is over expressed (60-100 times) in prostate tumors. The test is highly specific and uses Transcription Mediated Amplification (TMA) to quantify the PCA3 mRNA in a patient urine sample. The resulting output is a PCA3 score that can be used in conjunction with other patient history to predict biopsy outcomes.

Progensa(TM) PCA3 is CE-marked and currently available in the UK, The Netherlands, Germany, France and Belgium.

LOOKING FOR EXPERT ADVICE? Experts here are available to answer all your questions! Please contact us for more information about this feature, or to become an expert.

MEDIA CENTER Interactive Media  Blogs  · AACC 2010  Archives  · August 2010  · July 2010  · June 2010  · May 2010  · April 2010  · March 2010  · February 2010  · January 2010  · December 2009  · November 2009  · All Archives  Newsletter  · CLPrime  · Monthly Top Ten  Videos  · Analyzers  · Chemistry  · Point-of-Care Testing  · Miscellaneous   Podcast Series  · 2010 AACC Podcast Series  · Insights on Digital Pathology  · The Current State of the H1N1 Pandemic  · Medical Billing and Coding: Preparing for ICD-10 and X12 5010 Conversions  · Lab Information Systems  · Recent Developments in Personalized Medicine  · AACC podcast  · Stimulus Podcast  · Circulating Tumor Cell Detection  · Going Green Podcast Series  · Tumor Tissue of Origin Testing: Technology from Pathwork Diagnostics Resources Calendar Consumer Resources Media Kit Advertiser Index EAB Reprints